12:00 , Aug 22, 2019 |  BC Extra  |  Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

Increased momentum in the kidney disease space, sparked in part by an evolution in FDA's thinking about approvable endpoints, encouraged a VC syndicate to back newly launched Chinook with $65 million in series A funding....
00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
19:11 , Dec 14, 2018 |  BC Week In Review  |  Financial News

NASH company Akero raises $70M, plans Phase IIa trial

Akero Therapeutics Inc. (San Francisco, Calif.) raised $70 million in a series B round to move non-alcoholic steatohepatitis compound AKR-001 into a Phase IIa trial in mid-2019. The round was led by Janus Henderson Investors...
18:27 , Dec 12, 2018 |  BC Extra  |  Financial News

NASH company Akero raises $70M, plans Phase IIa trial

Akero Therapeutics Inc. (San Francisco, Calif.) raised $70 million in a series B round to move non-alcoholic steatohepatitis compound AKR-001 into a Phase IIa trial in mid-2019. The round was led by Janus Henderson Investors...
22:02 , Dec 6, 2018 |  BC Week In Review  |  Clinical News

Stoke unveils Dravet data that supported $90M series B

Stoke Therapeutics Inc. (Bedford, Mass.) presented the preclinical data for its Dravet syndrome antisense oligonucleotide (ASO) therapy that CEO Ed Kaye said helped it raise its $90 million series B round in October. In a...
14:49 , Dec 4, 2018 |  BC Extra  |  Preclinical News

Stoke unveils Dravet data that supported $90M series B

Stoke Therapeutics Inc. (Bedford, Mass.) presented the preclinical data for its Dravet syndrome antisense oligonucleotide (ASO) therapy that CEO Ed Kaye said helped it raise its $90 million series B round in October. In a...
19:08 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Stoke prepares for IND, IPO with $90M series B

Stoke Therapeutics Inc. (Bedford, Mass.) is eyeing an IPO next half after raising $90 million in a series B round on Oct. 23 from a slew of new investors. The company's Targeted Augmentation of Nuclear...
10:00 , Oct 23, 2018 |  BC Extra  |  Financial News

Stoke prepares for IND, IPO with $90M series B

Stoke Therapeutics Inc. (Bedford, Mass.) is eyeing an IPO next half after raising $90 million in a series B round from a slew of new investors. The company's Targeted Augmentation of Nuclear Gene Output (TANGO)...
18:32 , Sep 28, 2018 |  BioCentury  |  Emerging Company Profile

Stopping chain swapping

By controlling how antibody chains pair, Elstar Therapeutics Inc.’s platform can produce multispecific antibodies at yields comparable to methods for manufacturing monospecific antibodies. The company develops multispecific antibodies with up to four functional domains that...
17:35 , Sep 28, 2018 |  BC Week In Review  |  Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Sept. 26, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400...